Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US-2024352036-A1 · Oct 24, 2024 · US
Use of melanocortins to treat insulin sensitivity
US9155777B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9155777-B2 |
| Application number | US-74091708-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 5, 2008 |
| Priority date | Nov 5, 2007 |
| Publication date | Oct 13, 2015 |
| Grant date | Oct 13, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating insulin resistance in a subject in need thereof, comprising peripheral administration of an effective amount of Ac-Arg-c(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH 2 (SEQ ID NO:50) or a pharmaceutically acceptable salt thereof to treat said insulin resistance in said subject. 2. The method according to claim 1 , wherein said subject is obese or overweight. 3. The method according to claim 1 , wherein s…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9155777B2 cover?
- The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
- Who is the assignee on this patent?
- Halem Heather A, Culler Michael Dewitt, Butler Andrew A, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).